| Literature DB >> 26078031 |
Zhi Mao1,2, Guoqi Wang3, Lihai Zhang4, Licheng Zhang5, Shuo Chen6, Hailong Du7, Yanpeng Zhao8, Peifu Tang9.
Abstract
BACKGROUND: The choice between intramedullary (IM) nailing or plating of distal tibia fractures without articular involvement remains controversial. A meta-analysis of randomized controlled trials (RCTs) and observational studies was performed to compare IM nailing with plating for distal tibia fractures without articular involvement and to determine the dominant strategy.Entities:
Mesh:
Year: 2015 PMID: 26078031 PMCID: PMC4481115 DOI: 10.1186/s13018-015-0217-5
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1Study selection and inclusion process
Characteristics of included studies
| Study | Study design | No. of patients (I | Mean age (year) (I | Female (%) | Fracture types | GAT | Comparisons | Follow-up (month) | ROF (%) | |
|---|---|---|---|---|---|---|---|---|---|---|
| IM nailing | Plating | |||||||||
| Im et al. 2005 [ | RCT | 64 (34 | 42 | 28.1 | OTA 43-A1, -A2, -A3, -C1 | Closed, or type 1 | ACE tibial/cannulated nails | Anatomic plates | 24 | 100 |
| Guo et al. 2010 [ | RCT | 85 (44 | 44.2 | 35 | OTA 43-A1, -A2, -A3 | Closed | S2 nailing system | Percutaneous locking compression plates | 12 | 76.6 |
| Vallier et al. 2012 [ | RCT | 104 (56 | 38.1 | 18.3 | OTA 42-A, -B, -C | Closed, type 1, 2, or 3A | Intramedullary nails | Nonlocking plates | 12–71 | 96.2 |
| Mauffrey et al. 2012 [ | RCT | 24 (12 | 50 | 33.3 | OTA 42-A, -B, -C and OTA43-A | Closed, or type 1 | Intramedullary nails | Percutaneous locking plates | 12 | 100 |
| Li 2014 [ | RCT | 82 (40 | 44 | 15.3 | OTA 42-A, -B, -C | Closed, type 1, 2 | Intramedullary nails | Plate | 14.8 | 88.3 |
| Yang et al. 2006 [ | RP | 27 (13 | 54.6 | 44.4 | OTA 43-A | Closed | Shortened intramedullary nails | Nonlocking plates | 33 (16–60) | 100 |
| Janssen et al. 2007 [ | RP | 24 (12 | 40.8 | 50 | OTA 42-A and -B | Closed, or type 1 | Intramedullary nails | Plates | 20–112 | 100 |
| Zhang 2007 [ | RP | 51 (27 | 42.7 | 39.2 | AO A1-3,C1 | Closed, type 1, 2 | Intramedullary nails | Plates | 21.2 (12–27) | 100 |
| Vallier et al. 2008 [ | RP | 113 (76 | 38.4 | 30 | OTA 42-A, -B, and -C | Closed, type 1, 2, 3A, or 3B | Intramedullary nails | Nonlocking plates | 24 (12–84) | 100 |
| Chen et al. 2008 [ | RP | 46 (25 | 31 | 17.4 | AO A and B | Closed | Intramedullary nails | Plates | 12–36 | 100 |
| Huang 2008 [ | RP | 57 (30 | 42.7 | 36.8 | AO A and B | Closed, type 1, 2 | Intramedullary nails | Plates | 21.8 (10–28) | 100 |
| Ni 2010 [ | RP | 57 (32 | 45.8 | 33.3 | AO A1, A2, A3 | Closed, type 1, 2, 3A, | Intramedullary nails | Plates | 25 (12–33) | 96.5 |
| Feng 2011 [ | RP | 50 (22 | 43 V. 45 | 40 | AO A1, A2, A3, C1 | Closed, type 1, 2 | Intramedullary nails | Locking compression plate | 22.8 (12–48) | 100 |
| Wu 2011 [ | RP | 43 (25 | 46 | 41.9 | AO A1, B1, B2, C1 | Closed, type 1, 2 | Intramedullary nails | Locking compression plate | 16.2 (10–22) | 100 |
| Huang 2012 [ | RP | 52 (26 | 41.7 | 44.2 | AO 42A1-3, 43A1, 43A2 | Closed, type 1, 2 | Intramedullary nails | Locking plate | 12 | 100 |
| Jin 2012 [ | RP | 170 (72 | 47.5 | 42.9 | AO 41A, 42B, 43A-C | NA | Intramedullary nails | Locking compression plate | 8–14 | 100 |
| Li 2012 [ | RP | 46 (23 | 37 | 21.7 | AO 43A1-3 | Closed, type 1, 2 | Locked nailing | Locking compression plate | 24.7 | 100 |
| Ren 2012 [ | RP | 58 (28 | 31.9 | 34.5 | AO A, B, and C | Closed, type 1, 2 | Intramedullary nails | Plates | 6–36 | 100 |
| Seyhan et al. 2012 [ | RP | 61 (25 | 40.3 | 44.4 | OTA 42-A, -B, and -C | Closed, type 1, 2, or 3A | Expert, Synthes, and Trigen (Smith and Nephew) nails | Percutaneous locking plates | 21.24 (12–60) | 100 |
| Tan 2012 [ | RP | 96 (48 | 43.7 | 43.8 | AO A1-3, B1 | Closed and Open | Intramedullary nails | Plate | 12–24 | 100 |
| Yang 2012 [ | RP | 32 (17 | 39 | 40.6 | AO 42A B | Closed, type 1, 2 | Intramedullary nails | Locking plate | 15.1 (14–20) | 100 |
| Ke 20113 [ | RP | 62 (32 | 45.8 | 37.1 | AO A1, A2, A3 | Closed, type 1, 2 | Intramedullary nails | plate | 12 | 100 |
| Wang 2013 [ | RP | 98 (47 | 42.7 | NA | OTA 43A | NA | Intramedullary nails | Plate | 12 | 96.1 |
| Yao 2013 [ | RP | 126 (65 | 49.2 | 38.9 | OTA 42 A-C,43A | Closed, type 1, 2, or 3A | Intramedullary nails | Locking compression plates | 23.7 (12–53) | 100 |
| Zhu 2013 [ | RP | 74 (37 | 43.7 | 45.9 | 43A 1-3 | Closed and Open | Intramedullary nails | Plates | 6 (3–12) | 100 |
| Dong 2014 [ | RP | 46 (22 | 35.6 | 28.3 | AO A, B, and C | Closed | Intramedullary nails | compression plates | 8–36 | 100 |
| Guo 2014 [ | RP | 60 (30 | 45.2 | 41.7 | AO A1-A3 | Closed | Intramedullary nails | Locking compression plates | 12 | 100 |
| Yavuz 2014 [ | RP | 55 (21 | 38 | 41.8 | OTA 42 A-C | Closed type 1, 2 | Intramedullary nails | Plates | 27.6 (12–82) | 100 |
GAT Gustilo and Anderson Type, I V. P IM nailing versus plating, ROF rate of follow-up, V. versus, RCT randomized controlled trial, RP retrospective
Fig. 2Risk of bias: summary for randomized controlled trials. plus sign low risk, question mark unclear risk
MINORS appraisal scores for the included retrospective studies
| Study | Methodologic itemsa | Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ||
| Yang et al. 2006 [ | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Janssen et al. 2007 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Zhang 2007 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 1 | 16 |
| Vallier et al. 2008 [ | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 18 |
| Chen et al. 2008 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Huang 2008 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Ni 2010 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Feng 2011 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Wu 2011 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 1 | 16 |
| Huang 2012 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Jin 2012 [ | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Li 2012 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Ren 2012 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 1 | 16 |
| Seyhan et al. 2012 [ | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Tan 2012 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Yang 2012 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Ke 20113 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Wang 2013 [ | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 16 |
| Yao 2013 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Zhu 2013 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Dong 2014 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Guo 2014 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
| Yavuz 2014 [ | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 17 |
aMethodologic items: (1) a clearly stated aim; (2) inclusion of consecutive patients; (3) prospective collection of data; (4) endpoints appropriate to the aim of the study; (5) unbiased assessment of the study endpoint; (6) follow-up period appropriate to the aim of the study; (7) loss to follow up, which is less than 5 %; (8) prospective calculation of the study size; (9) an adequate control group; (10) contemporary groups; (11) baseline equivalence of groups; and (12) adequate statistical analyses. The items are scored as “0” (not reported), “1” (reported but inadequate), or “2” (reported and adequate). The global ideal score for comparative studies is 24 [41]
The GRADE evidence quality for complications
| Complications | Number of studies | Study design | Risk Ratio [95 % CI] |
|
| Quality |
|---|---|---|---|---|---|---|
| Deep infection | 4 [2,10,35,38] | RCT | 0.79 [0.27, 2.29] | 0.67 | 0.72 | Moderatea |
| 4 [9,12,28,29] | Retrospective | 0.44 [0.14, 1.41] | 0.17 | 0.43 | Moderateb | |
| Delayed wound healing and superficial infection | 4 [2,10,33,38] | RCT | 0.41 [0.11, 1.61] | 0.20 | 0.13 | Moderatea |
| 14 [12,14-19,21,24-28,31,32] | Retrospective | 0.34 [0.21, 0.57] | <0.0001 | 0.61 | Moderateb | |
| Delayed union | 4 [2,10,35,38] | RCT | 1.46 [0.70, 3.03] | 0.31 | 0.37 | Moderatea |
| 8 [9,12,13,17,19,28-30] | Retrospective | 0.99 [0.62, 1.59] | 0.98 | 0.72 | Low | |
| Removal of metal work | 3 [2,33,35] | RCT | 0.89 [0.62, 1.27] | 0.51 | 0.39 | Moderatea |
| 6 [9,12,13,17,23,27] | Retrospective | 0.89 [0.36, 2.17] | 0.79 | 0.08 | Low | |
| Secondary procedures | 4 [2,33,35,38] | RCT | 0.92 [0.62, 1.37] | 0.69 | 0.13 | Moderatea |
| 6 [9,12,13,17,23,27] | Retrospective | 0.78 [0.33, 1.80] | 0.55 | 0.02 | Low | |
| Malunion | 4 [2,10,35,38] | RCT | 1.52 [0.81, 2.85] | 0.20 | 0.64 | Moderatea |
| 14 [9,11-14,16,18,20,22,24,26,28,29,31,32] | Retrospective | 4.79 [2.86, 8.01] | <0.00001 | 1.00 | Moderatec | |
| Knee pain | 2 [35,38] | RCT | 5.39 [0.13, 229.08] | 0.38 | 0.009 | Lowa,d |
| 6 [11,13-15,28,29] | Retrospective | 4.01 [1.71, 9.40] | 0.001 | 0.14 | Moderatec |
aTotal number of events is less than 300
bRR < 0.5
cRR > 2
d I 2 > 50 %
The GRADE evidence quality for functional outcomes
| Functional outcomes | Number of studies | Study design | Mean difference [95 % CI] |
|
| Quality |
|---|---|---|---|---|---|---|
| Olerud and Molander Ankle Score | 4 [14,16,21,25] | Retrospective | 0.01 [−0.02, 0.03] | 0.56 | 0.09 | Low |
| American Orthopaedic Foot and Ankle Surgery score | 2 [27,28] | Retrospective | 4.10 [0.03, 8.17] | 0.05 | 0.10 | Low |
| Radiologic union | 3 [10,33,38] | RCT | −0.53 [−2.39, 1.34] | 0.58 | <0.00001 | Lowa,b |
| 8 [14,16,20,22,24,25,29,32] | Retrospective | −0.98 [−3.61, 1.66] | 0.47 | <0.00001 | Low |
aTotal number of events is less than 300
b I 2 > 50 %
Fig. 3Delayed wound healing and superficial infection: IM nailing versus plating
Fig. 4Malunion: IM nailing versus plating
Fig. 5Knee pain: IM nailing versus plating
Fig. 6Funnel plot for delayed union